Characteristics of pemetrexed transport by renal basolateral organic anion transporter hOAT3

Drug Metabolism and Pharmacokinetics

Volumn 29, Issue 2, 2014, Pages 148-153

  Kurata, Tomohiko ^a   Iwamoto, Takuya ^a,b   Kawahara, Yuki ^a   Okuda, Masahiro ^a,b  

^a MIE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b MIE UNIVERSITY HOSPITAL   (Japan)

Author keywords

Drug interaction; Methotrexate; Organic anion transporter; Pemetrexed; Renal tubular secretion

Indexed keywords

CEFAZOLIN; IBUPROFEN; LOXOPROFEN; METHOTREXATE; ORGANIC ANION TRANSPORTER 1; ORGANIC ANION TRANSPORTER 3; PEMETREXED; PRAVASTATIN; FOLIC ACID ANTAGONIST; GLUTAMIC ACID DERIVATIVE; GUANINE; ORGANIC ANION TRANSPORTER;

ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG INHIBITION; DRUG TRANSPORT; EMBRYO; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; IC 50; PROTEIN EXPRESSION; TRANSPORT KINETICS; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; COMPARATIVE STUDY; DRUG EFFECTS; DRUG INTERACTION; GENETIC TRANSFECTION; GENETICS; HEK293 CELL LINE; KIDNEY; KINETICS; METABOLISM; TRANSPORT AT THE CELLULAR LEVEL;

BIOLOGICAL TRANSPORT; DRUG INTERACTIONS; FOLIC ACID ANTAGONISTS; GLUTAMATES; GUANINE; HEK293 CELLS; HUMANS; KIDNEY; KINETICS; METHOTREXATE; ORGANIC ANION TRANSPORT PROTEIN 1; ORGANIC ANION TRANSPORTERS, SODIUM-INDEPENDENT; TRANSFECTION;

EID: 84901229062     PISSN: 13474367     EISSN: 18800920     Source Type: Journal    
DOI: 10.2133/dmpk.DMPK-13-RG-042     Document Type: Article

References (33)

1. Shih, C., Habeck, L. L., Mendelsohn, L. G., Chen, V. J. and Schultz, R. M.: Multiple folate enzyme inhibition: mechanism of a novel pyrrolopyrimidine- based antifolate LY231514 (MTA). Adv. Enzyme Regul., 38: 135-152 (1998).
2. Adjei, A. A.: Pemetrexed (ALIMTA), a novel multitargeted antineoplastic agent. Clin. Cancer Res., 10: 4276s-4280s (2004).
3. Hanauske, A. R., Chen, V., Paoletti, P. and Niyikiza, C.: Pemetrexed disodium: a novel antifolate clinically active against multiple solid tumors. Oncologist, 6: 363-373 (2001).
4. Sweeney, C. J., Takimoto, C. H., Latz, J. E., Baker, S. D., Murry, D. J., Krull, J. H., Fife, K., Battiato, L., Cleverly, A., Chaudhary, A. K., Chaudhuri, T., Sandler, A., Mita, A. C. and Rowinsky, E. K.: Two drug interaction studies evaluating the pharmacokinetics and toxicity of pemetrexed when coadministered with aspirin or ibuprofen in patients with advanced cancer. Clin. Cancer Res., 12: 536-542 (2006).
5. Nakagawa, K., Kudoh, S., Matsui, K., Negoro, S., Yamamoto, N., Latz, J. E., Adachi, S. and Fukuoka, M.: A phase I study of pemetrexed (LY231514) supplemented with folate and vitamin B12 in Japanese patients with solid tumours. Br. J. Cancer., 95: 677-682 (2006).
6. Rinaldi, D. A., Kuhn, J. G., Burris, H. A., Dorr, F. A., Rodriguez, G., Eckhardt, S. G, Jones, S., Woodworth, J. R., Baker, S., Langley, C., Mascorro, D., Abrahams, T. and Von, Hoff, D.D.: A phase I evaluation of multitargeted antifolate (MTA, LY231514), administered every 21 days, utilizing the modified continual reassessment method for dose escalation. Cancer Chemother. Pharmacol., 44: 372-380 (1999).
7. Mita, A. C., Sweeney, C. J., Baker, S. D., Goetz, A., Hammond, L. A., Patnail, A., Tolcher, A. W., Villalona-Calero, M., Sandler, A., Chaudhuri, T., Molpus, K., Latz, J. E., Simms, L., Chaudhary, A. K., Johnson, R. D., Rowinsky, E. K. and Takimoto, C. H.: Phase 1 and pharmacokinetic study of pemetrexed administered every 3 weeks to advanced cancer patients with normal and impaired function. J. Clin. Oncol., 24: 552-562 (2006).
8. Hosoyamada, M., Sekine, T., Kanai, Y. and Endou, H.: Molecular cloning and functional expression of a multispecific organic anion transporter from human kidney. Am. J. Physiol., 276: F122-F128 (1999).
9. Cha, S. H., Sekine, T., Fukushima, J. I., Kanai, Y., Kobayashi, Y., Goya, T. and Endou, H.: Identification and characterization of human organic anion transporter 3 expressing predominantly in the kidney. Mol. Pharmacol., 59: 1277-1286 (2001).
10. Uwai, Y., Okuda, M., Takami, K., Hashimoto, Y. and Inui, K.: Functional characterization of the rat multispecific organic anion transporter OAT1 mediating basolateral uptake of anionic drugs in the kidney. FEBS Lett., 438: 321-324 (1998).
11. Uwai, Y., Taniguchi, R., Motohashi, H., Saito, H., Okuda, M. and Inui, K.: Methotrexate-loxoprofen interaction: involvement of human organic anion transporters hOAT1 and hOAT3. Drug Metab. Pharmacokinet., 19: 369-374 (2004).
12. Maiche, A. G.: Acute renal failure due to concomitant action of methotrexate and indomethacin. Lancet, 1: 1390 (1986).
13. Thyss, A., Milano, G., Kubar, J., Namer, M. and Schneider, M.: Clinical and pharmacokinetic evidence of a life-threatening interaction between methotrexate and ketoprofen. Lancet, 327: 256-258 (1986).
14. Drug Interaction Studies - Study Design, Data Analysis, Implications for Dosing, and Labeling Recommendations, DRAFT GUIDANCE, US Department of Health and Human Services, FDA, and Center for Drug Evaluation and Research (CDER), Feb. 2012. Available at: http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/UCM292362.pdf (accessed 15 Jul 2013).
15. Kimura, N., Okuda, M. and Inui, K.: Metformin transport by renal basolateral organic cation transporter hOCT2. Pharm. Res., 22: 255-259 (2005).
16. Bradford, M. M.: A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem., 72: 248-254 (1976).
17. Li, H., Luo, W., Zeng, Q., Lin, Z., Luo, H. and Zhang, Y.: Method for the determination of blood methotrexate by high performance liquid chromatography with online post-column electrochemical oxidation and fluorescence detection. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci., 845: 164-168 (2007).
18. Respaud, R., Tournamille, J. F., Croix, C., Laborie, H., Elfakir, C. and Viaud-Massuard, M. C.: Development of an ion-pairing reversed-phase liquid chromatography method using a double detection analysis (UV and evaporative light scattering detection) to monitor the stability of Alimta(®)-pemetrexed preparations: identification and quantification of L-glutamic acid as a potential degradation product. J. Pharm. Biomed. Anal., 54: 411-416 (2011).
19. Uwai, Y. and Iwamoto, K.: Transport of aminopterin by human organic anion transporters hOAT1 and hOAT3: Comparison with methotrexate. Drug Metab. Pharmacokinet., 25: 163-169 (2010).
20. Motohashi, H., Sakurai, Y., Saito, H., Masuda, S., Urakami, Y., Goto, M., Fukatsu, A., Ogawa, O. and Inui, K.: Gene expression levels and immunolocalization of organic ion transporters in the human kidney. J. Am. Soc. Nephrol., 13: 866-874 (2002).
21. Uwai, Y., Ida, H., Tsuji, Y., Katsura, T. and Inui, K.: Renal transport of adefovir, cidofovir, and tenofovir by SLC22A family members (hOAT1, hOAT3, and hOCT2). Pharm. Res., 24: 811-815 (2007).
22. Ueo, H., Motohashi, H., Katsura, T. and Inui, K.: Human organic anion transporter hOAT3 is a potent transporter of cephalosporin antibiotics, in comparison with hOAT1. Biochem. Pharmacol., 70: 1104-1113 (2005).
23. Takeda, M., Noshiro, R., Onozato, M. L., Tojo, A., Hasannejad, H., Huang, X. L., Narikawa, S. and Endou, H.: Evidence for a role of human organic anion transporters in the muscular side effects of HMG-CoA reductase inhibitors. Eur. J. Pharmacol., 483: 133-138 (2004).
24. Tracy, T. S., Krohn, K., Jones, D. R., Bradley, J. D., Hall, S. D. and Brater, D. C.: The effects of a salicylate, ibuprofen, and naproxen on the disposition of methotrexate in patients with rheumatoid arthritis. Eur. J. Clin. Pharmacol., 42: 121-125 (1992).
25. Kremer, J. M. and Hamilton, R. A.: The effects of nonsteroidal antiinflammatory drugs on methotrexate (MTX) pharmacokinetics: impairment of renal clearance of MTX at weekly maintenance doses but not at 7.5 mg. J. Rheumatol., 22: 2072-2077 (1995).
26. Dewland, P. M., Reader, S. and Berry, P.: Bioavailability of ibuprofen following oral administration of standard ibuprofen, sodium ibuprofen or ibuprofen acid incorporating poloxamer in healthy volunteers. BMC Clin. Pharmacol., 9: 19-28 (2009).
27. Kim, I. W., Chung, S. J. and Shim, C. K.: Altered metabolism of orally administered loxoprofen in human subjects after an oral administration of loxoprofen for three consecutive days followed by a seven-day washout. J. Pharm. Sci., 91: 973-979 (2002).
28. Vella-Brincat, J. W., Begg, E. J., Kirkpatrick, C. M., Zhang, M., Chambers, S. T. and Gallagher, K.: Protein binding of cefazolin is saturable in vivo both between and within patients. Br. J. Clin. Pharmacol., 63: 753-757 (2007).
29. Nozaki, Y., Kusuhara, H., Endou, H. and Sugiyama, Y.: Quantitative evaluation of the drug-drug interactions between methotrexate and nonsteroidal anti-inflammatory drugs in the renal uptake process based on the contribution of organic anion transporters and reduced folate carrier. J. Pharmacol. Exp. Ther., 309: 226-234 (2004).
30. Bakos, E., Evers, R., Sinko, E., Varadi, A., Borst, P. and Sarkadi, B.: Interactions of the human multidrug resistance proteins MRP1 and MRP2 with organic anions. Mol. Pharmacol., 57: 760-768 (2000).
31. Mitomo, H., Kato, R., Ito, A., Kasamatsu, S., Ikegami, Y., Kii, I., Kudo, A., Kobatake, E., Sumino, Y. and Ishikawa, T.: A functional study on polymorphism of the ATP-binding cassette transporter ABCG2: critical role of arginine-482 in methotrexate transport. Biochem. J., 373: 767-774 (2003).
32. Volk, E. L. and Schneider, E.: Wild-type breast cancer resistance protein (BCRP/ ABCG2) is a methotrexate polyglutamate transporter. Cancer Res., 63: 5538-5543 (2003).
33. Nozaki, Y., Kusuhara, H., Kondo, T., Iwaki, M., Shiroyanagi, Y., Nakayama, H., Horita, S., Nakazawa, H., Okano, T. and Sugiyama, Y.: Species difference in the inhibitory effect of nonsteroidal antiinflammatory drugs on the uptake of methotrexate by human kidney slices. J. Pharmacol. Exp. Ther., 322: 1162-1170 (2007).